MBX Biosciences (MBX) Profit After Tax (2023 - 2026)

MBX Biosciences has reported Profit After Tax for 4 years, with the latest figure at -$23.5 million in Q1 2026.

• Quarterly Profit After Tax rose 1.52% year-over-year to -$23.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$86.7 million (up 14.62% YoY) and the FY2025 annual result came in at -$87.0 million, down 40.49% from the prior year.
• Profit After Tax eased to -$23.5 million in Q1 2026 per MBX's latest filing, from -$22.2 million in the prior quarter.
• Over five years, Profit After Tax peaked at $121000.0 in Q3 2024 and troughed at -$62.0 million in Q4 2024.
• A 4-year average of -$20.0 million and a median of -$19.4 million in 2025 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2024 and 2025: Profit After Tax soared 101.19% in 2024, then plunged 17966.12% in 2025.
• Over 4 years, Profit After Tax stood at -$8.8 million in 2023, then plunged by 600.81% to -$62.0 million in 2024, then surged by 64.19% to -$22.2 million in 2025, then dropped by 5.98% to -$23.5 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$23.5 million, -$22.2 million, and -$21.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.